GlassScriptPhysician profile
Jordan Bushman
NPI 1679003941
$1,862.43
in general payments reported to CMS, 2019-2025
27 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $607 · 2024: $809 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Education: $15.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.02 |
| Education | $15.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $214.66 | 2023-2024 | Minimed 780g |
| Abbvie INC. | $188.80 | 2023-2024 | Rinvoq |
| Lilly USA, LLC | $162.14 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $147.19 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Biotech, INC. | $111.19 | 2023-2024 | Tremfya |
| Ucb, INC. | $108.22 | 2023-2025 | Bimzelx, Cimzia |
| Insulet Corporation | $97.33 | 2024 | Omnipod |
| Sandoz INC. | $89.51 | 2024-2025 | Hyrimoz, Jubbonti |
| Ascendis Pharma Endocrinology INC | $73.64 | 2023-2025 | Yorvipath |
| Beta Bionics, INC. | $70.14 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $67.07 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $66.72 | 2023 | |
| Radius Health, INC. | $64.91 | 2023-2024 | Tymlos |
| Dexcom, INC. | $57.84 | 2024 | Dexcom G6 Transmitter |
| Kiniksa Pharmaceuticals International, Plc | $51.13 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.46 | 2023 | Strensiq |
| Neurocrine Biosciences, INC. | $33.66 | 2025 | |
| Tandem Diabetes Care, INC. | $31.50 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $30.01 | 2024 | Xyosted |
| Averitas Pharma INC. | $24.77 | 2023 | Qutenza |
| Amphastar Pharmaceuticals, INC. | $22.19 | 2025 | |
| Tolmar, INC. | $20.79 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $20.59 | 2025 | Imcivree |
| Alvogen INC | $18.54 | 2024 | Teriparatide |
| Genentech USA, INC. | $18.39 | 2023 | Actemra |
| Amgen INC. | $16.63 | 2023 | Amjevita, Otezla |
| Celltrion USA INC. | $15.41 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Bushman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.